Long arginine 3-IGF-1, abbreviated as IGF-1 LR3 or LR3-IGF-1, is a synthetic protein and lengthened analogue of human insulin-like growth factor 1 (IGF-1). It differs from native IGF-1 in that it possesses an arginine instead of a glutamic acid at the third position in its amino acid sequence (“arginine 3”), and also has an additional 13 amino acids at its N-terminus (MFPAMPLLSLFVN) (“long”), for a total of 83 amino acids (relative to the 70 of IGF-1). The consequences of these modifications are that IGF-1 LR3 retains the pharmacological activity of IGF-1 as an agonist of the IGF-1 receptor, has very low affinity for the insulin-like growth factor-binding proteins (IGFBPs), and has improved metabolic stability. As a result, it is approximately three times more potent than IGF-1, and possesses a significantly longer half-life of about 20–30 hours (relative to IGF-1’s half-life of about 12–15 hours).
The amino acid sequence of IGF-1 LR3 is MFPAMPLSSL FVNGPRTLCG AELVDALQFV CGDRGFYFNK PTGYGSSSRR APQTGIVDEC CFRSCDLRRL EMYCAPLKPA KSA.IGF-1LR3 for sale.
Mechanism of action
IGF-1 LR3 binds to cell receptors in the muscle cells and activates cell communication, which then improves the growth rate of muscles.IGF-1 LR3 obstructs the movement of glucose into the body’s cells. This facilitates fat burning and the use of fat in the body for the production of energy. IGF-1 LR3 has a life in the body for about 20-30 hours and therefore enhance the growth amount of muscle for a whole day.
Description Long arginine 3-IGF-1, abbreviated as IGF-1 LR3 or LR3-IGF-1, is a synthetic protein and lengthened analogue of human insulin-like growth factor 1 (IGF-1). It differs from native IGF-1 in that it possesses an arginine instead of a glutamic acid at the third position in its amino acid sequence (“arginine 3”), and also has an additional 13 amino acids at its N-terminus (MFPAMPLLSLFVN) (“long”), for a total of 83 amino acids (relative to the 70 of IGF-1).
Uses
The consequences of these modifications are that IGF-1 LR3 retains the pharmacological activity of IGF-1 as an agonist of the IGF-1 receptor, has very low affinity for the insulin-like growth factor-binding proteins (IGFBPs), and has improved metabolic stability.As a result, it is approximately three times more potent than IGF-1,and possesses a significantly longer half-life of about 20–30 hours (relative to IGF-1’s half-life of about 12–15 hours).
benefits Based on the literature, IGF1-LR3 has been shown to:
Increase Fat Loss
Aid in the development of lean muscle mass
Add protection against muscle wasting
Reduce inflammation
Side effects Some possible side effects of IGF-1 LR3 may include the following: muscle and joint pain, nausea, headaches, hypoglycemia (usually when IGF-1 LR3 is administered in continuous high doses) and may be associated with increased risk of developing some cancers.
More Introduction:https://en.wikipedia.org/wiki/IGF-1_LR3
